That production ann on Oct 11 has probably "stolen the thunder" from the quarterly, imho. The costs associated with the CR might also sour things.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%
TLS Telstra to boost phone plan prices despite inflation – and despite claiming they wouldn't 2 months ago